Reuters Health Information: Europe gives green light to AbbVie hepatitis C medicine, others
Europe gives green light to AbbVie hepatitis C medicine, others
Last Updated: 2014-11-21
By Reuters Staff
LONDON (Reuters) - European regulators recommended approval
for AbbVie's hepatitis C drug dasabuvir, an experimental
all-oral regimen for patients infected with the virus that could
be an alternative to long courses of a combination of pills and
Sanofi's eliglustat, a medicine to treat the rare genetic
disorder Gaucher disease type 1 that was approved in the United
States in August, was also recommended in Europe.
Boehringer Ingelheim's drug nintedanib for idiopathic
pulmonary fibrosis (IPF), and Merck & Co's blood clot preventer
vorapaxar, were also all recommended for approval on Friday.
The regulator also gave the nod to Novartis' psoriasis drug
secukinumab, which was recommended for approvals by the U.S.
Food and Drug Administration last month, and Celgene's
apremilast to treat psoriatic arthritis.
Recommendations for marketing approval by the European
Medicine Agency's Committee for Medicinal Products for Human Use
are usually endorsed by the European Commission within a couple